Welcome to our dedicated page for BioRegenx SEC filings (Ticker: BRGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioRegenx, Inc. (BRGX) SEC filings page on Stock Titan is intended to provide access to the company 27s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BioRegenx describes itself as a health-technology and health information services company focused on microvascular, metabolic, and cellular health through patented diagnostics, nutraceuticals, and AI-powered digital health tools.
In its public statements, BioRegenx notes that it has remained current with its SEC reporting obligations since completing its merger with Findit, Inc. (FDIT). The company also reports that it engaged a new PCAOB-registered independent auditing firm following industry-wide enforcement actions that affected prior audit providers, and that this auditor engagement was disclosed in a Form 10-K filing. These points underscore the role of periodic and annual reports in documenting its financial condition, governance, and risk factors.
On this page, users can review core SEC filings such as annual reports (Form 10-K) and quarterly reports (Form 10-Q) when available, along with other relevant submissions. These documents typically outline segment information, technology assets, licensing arrangements, and details related to mergers or subsidiary structures, such as the acquisition of DocSun Biomedical Holdings and the licensing of the GlycoCheck ae vascular diagnostic system.
Stock Titan enhances access to these filings with AI-powered summaries designed to highlight key themes, clarify complex sections, and help users quickly understand disclosures related to BioRegenx 27s diagnostic platforms, AI technologies, and capital markets activities. As new filings are made available through EDGAR, this page updates to reflect the latest regulatory information for BRGX.
BioRegenx, Inc. reported Q3 results showing smaller losses and lean liquidity. Net sales were $507,755 versus $596,037 a year ago, with gross profit of $426,397. Operating expenses declined sharply due to the absence of prior-year amortization, narrowing loss from operations to $8,459 from $327,307. Net loss was $80,565 versus $394,860 in the prior-year quarter.
For the nine months, net sales were $1,468,872 versus $1,879,617, and net loss was $525,764 versus $4,653,446. Cash was $46,947 and stockholders’ deficit was $3,647,136 as of September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting $522,500 of notes in default and EIDL delinquencies of $400,000, both classified as current. Total liabilities were $4,814,900.
The company recorded a GlycoCheck sublicense with a three-year minimum royalty of $750,000, recognizing an intangible asset of $725,000 (net) and a $700,000 royalty liability. Common shares outstanding were 961,992,601 as of November 9, 2025.